Pentixapharm Streamlines Operations with Workforce Reduction and Pipeline Focus

The Managing Board and Supervisory Board of Pentixapharm Holding AG jointly resolved to significantly reduce early-stage research and development activities and concentrate resources on the company's most advanced clinical programs. This strategic prioritization allows Pentixapharm to invest more effectively in its most value-generating development programs, including the Phase 3-ready CXCR4 flagship program for the improved diagnosis of treatment-resistant hypertension. This decision represents a continuation of the clinical development strategy introduced in May 2025, which prioritizes high-value CXCR4-targeted programs.

The sharpened focus includes an adjustment of the organizational structure, accompanied by a targeted workforce reduction of approximately 50% at Pentixapharm AG. Implementation is anticipated to be completed in the first quarter of 2026. The adjustments are expected to lower annual operating costs and extend the company's cash runway through the first quarter of 2027. These measures mark a targeted continuation of the clinical development strategy outlined earlier this year, positioning the company for more sustainable growth while maintaining focus on its most promising assets.

Dr. Dirk Pleimes, CEO and CMO of Pentixapharm AG, emphasized the strategic importance of these changes, stating that optimizing operational costs is crucial for enhancing company efficiency and achieving upcoming clinical milestones. The Phase 3-ready PentixaFor CXCR4 program for the diagnosis of treatment-resistant hypertension has made significant progress in recent months and remains a central value driver, showcasing Pentixapharm's clinical development expertise. While the organizational restructuring represents a carefully considered decision, it is essential for safeguarding the company's long-term value and supporting sustainable growth.

The company's clinical pipeline is anchored by CXCR4-targeted PET-CT programs, including the advanced candidate for improved diagnosis of hypertensive patients with primary aldosteronism, which is intended to enable targeted treatment of the underlying causes of hypertension. CXCR4-based developments also include pioneering therapeutic programs in hematological cancers, complemented by CXCR4 and CD24 intellectual property protection and a reliable isotope supply chain. These strategic adjustments reflect the company's commitment to delivering meaningful patient benefit while navigating the challenges of clinical-stage biotech development in one of the fastest-growing areas of precision medicine.